The influence of ofloxacin (Tarivid) on the parasite-host inter-relationship in patients with chronic urinary tract infection.
In urinary tract infection (UTI), the aim of antimicrobial chemotherapy is either to attenuate the virulence of infective micro-organisms, to influence the interaction between germs and host or to kill bacteria. In 25 females (aged 49.8+/-14.7 years) with chronic UTI, parameters of inflammation (CRP, alpha 2-globulin, leukocytes, ESR) as well as renal function were analyzed under the treatment with ofloxacin 2 x 200 mg. Subsequently, bacterial attachment, bacterial count, leukocytes, antibody-coated bacteria (ACB), immunoglobulin (Ig) G, albumin, a2-microglobulin, Tamm Horsfall protein, secretory IgA (sIgA) and lysozyme were determined in urine. The micro-organisms were examined with regard to the expression of hemolysin, aerobactin, P-fimbriae and according to their plasmid profile. Ofloxacin serum levels were analyzed once prior to, on day 6 during and on day 3 after drug administration. In all cases, the acute clinical symptoms had disappeared after 10 days of treatment, all bacteria were eliminated, and the parameters of inflammation in serum and urine had returned to normal. On the sixth day of therapy, no expression of P-fimbriae was detectable in the Escherichia coli strains isolated, and the attachment rate decreased from 42+/-30.9% to 11.1+/-18.1%. The sIgA level rose from 42.6+68.5 prior to therapy to 88.8+/-136.8 mmol/l on day 3 after therapy; acute symptoms of UTI did not recur in any case during the period of 1 year.
Fünfstück
R
R
Friedrich-Schiller Universität Jena, Klinik für Innere Medizin IV, Germany.
Wolfram
M
M
Gerth
J
J
Schubert
K
K
Straube
E
E
Stein
G
G
D000328:Adult; D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use* / Q000652:urine; D001422:Bacterial Adhesion / Q000187:drug effects; D015169:Colony Count, Microbial; D005260:Female; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000378:metabolism; D008875:Middle Aged; D009088:Mucoproteins / Q000652:urine; D015242:Ofloxacin / Q000097:blood / Q000494:pharmacology / Q000627:therapeutic use* / Q000652:urine; D014552:Urinary Tract Infections / Q000188:drug therapy*; D058949:Uromodulin; D014774:Virulence
D000892:Anti-Infective Agents, Urinary; D007071:Immunoglobulin A, Secretory; D009088:Mucoproteins; C548612:UMOD protein, human; D058949:Uromodulin; D015242:Ofloxacin